Checks out so far.

“In a retrospective metastatic prostate-cancer cohort, among cases classified as IMF6-high, androgen-receptor pathway inhibitor treatment was associated with lower treatment-failure risk than taxane treatment (HR 0.21, 95% CI 0.05–0.79, P = 0.021).”

2 of 4 review checks done · 1 counted · 1 by the author only

Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited. The number is model-conditional, not a share of truth.